Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay

In a prospective study of 109 subjects, an enzyme-linked immunosorbent assay (ELISA) was used to measure platelet-rich plasma (PRP) serotonin levels in patients with polycythaemia vera (PV; n = 27), essential thrombocythaemia (ET; n = 14), myelofibrosis with myeloid metaplasia (MMM; n = 30), secondary or spurious polycythaemia (SP; n = 22) and controls (n = 16). Nine study subjects who were taking a selective serotonin reuptake inhibitor (SSRI) all displayed a markedly decreased PRP serotonin level (median, 24.2 ng/10(9) platelets; range, 0-49.3) and were therefore excluded from further analysis. Among the remaining 100 subjects, the median and range of PRP serotonin levels, in ng/10(9) platelets, was significantly lower in MMM (89.5; 0-278.3), PV (204.8; 0-496.0) and ET (385.3; 136.8-1025.7) compared with both SP (608.8; 369.0-1780.1) and controls (567.2; 359.9-1071.1). Neutrophil polycythaemia rubra vera-1 (PRV-1) expression was concurrently assayed by real-time polymerase chain reaction in 69 patients (23 PV, 17 SP, 12 ET, seven MMM, 10 controls). PRP serotonin measurement performed as well as the PRV-1 assay in distinguishing PV from SP (93% vs. 86% test accuracy). The current study suggests that PRP serotonin concentration might be considered as one of the several biological markers that complement each other for the diagnosis of PV.     

The JAK2V617F mutation and thrombosis

Since the discovery of the JAK2^V617F mutation, the clinical and pathological consequences of this acquired defect have been extensively investigated to determine whether its presence characterises a distinct subgroup of myeloproliferative disorders (MPD). MPD management remains highly dependent on the patient’s thrombotic risk. Whether the presence of the JAK2^V617F mutation modifies the thrombotic risk is currently contentious, although there is increasing clinical evidence to suggest that the mutation may be variably associated with thrombosis. These observations are further supported by laboratory parameters which suggest that the JAK2^V617F mutation may confer increased activation of leucocytes and platelets in MPD. The role of screening for the JAK2^V617F mutation in patients presenting with thrombosis without overt MPD is unclear, but appears justified in cases of idiopathic splanchnic vein thrombosis.     

复方白芍颗粒质量控制研究

目的 建立复方白芍颗粒的质量标准.方法 采用薄层色谱法对制剂中的白芍、泽泻进行定性鉴别,采用高效液相色谱法测定制剂中芍药苷含量.结果 薄层色谱斑点清晰,且阴性对照无干扰;芍药苷浓度在33.35～333.50μg/mL范围内与峰面积的线性关系良好,平均回收率为97.39％(RSD=1.35％,n=6).结论 所建立的方法操作简单,重复性好,可有效控制复方白芍颗粒质量.     

四川市售白芍饮片质量调研

目的:调研四川市售白芍饮片质量。方法:随机采购四川市售白芍饮片16批,参照现行2010版药典的规定,测定饮片水分、总灰分、水溶性浸出物,并采用HPLC法测定芍药苷含量。结果:16批次白芍饮片中仅3批次芍药苷的量符合药典规定,9批次水分符合药典规定。结论:白芍饮片存在的质量问题主要是芍药苷含量和水分含量不合格。针对导致白芍药材或饮片质量问题的多种原因,药品监督管理部门应加强监督管理,规范饮片市场。     

经典名方当归四逆汤物质基准量值传递分析

目的 建立经典名方当归四逆汤物质基准的HPLC特征图谱及指标性成分含量测定方法,阐明当归四逆汤物质基准关键质量属性,为后续复方制剂的开发奠定基础。方法 制备18批当归四逆汤物质基准,建立HPLC特征图谱,进行特征峰归属及相似度评价;测定指标性成分的含量,对物质基准进行量值传递分析。结果 18批物质基准的特征图谱的相似度均大于0.90,共确定19个特征峰,分别来自方中当归（峰4、5、19）、桂枝（峰10、11、14）、白芍（峰6、9）、细辛（峰1、3、13、15、18）和炒甘草（峰7、8、12、16、17）;各指标成分从饮片到物质基准的转移率分别为芍药苷78.47%～96.01%、甘草苷43.79%～94.62%、阿魏酸81.20%～131.24%、肉桂酸70.03%～106.75%、桂皮醛3.17%～5.50%、甘草酸31.08%～52.43%、细辛脂素9.63%～13.37%。结论 采用特征图谱结合多指标性成分含量测定对当归四逆汤物质基准进行量值传递研究,该方法科学合理,为当归四逆汤物质基准的质量控制及复方制剂的开发提供科学依据。     

赤芍体外拮抗脂多糖的实验研究

目的 对分离提取出的中药赤芍中拮抗脂多糖的有效成分进行药理学活性检测。方法应用鲎实验和ELISA法检测该有效成分对LPS的中和作用。结果赤芍中的有效成分与LPS具有较高的结合作用,该结合作用具有较强的中和LPS活性,在体外能够显著抑制由LPS介导小鼠RAW264．7细胞释放TNF-α。结论证明赤芍中具有较强的中和LPS活性的有效成分。     

基于CiteSpace和VOSviewer的白芍研究现状及研究热点可视化分析

目的 基于CiteSpace和VOSviewer文献计量学方法,分析白芍研究现状并预测未来的研究热点和发展趋势。方法 分别从中国知网数据库、万方数据库、Web of Science数据库核心集中收集白芍研究文献,导入NoteExpress中删除重复文献、不合格文献并统一关键词,再利用Excel、CiteSpace、VOSviewer软件分别对中英文文献的发文量、发文期刊、发文作者、发文机构、发文国家、文献被引频次、关键词等进行可视化分析。结果 共检索到符合要求的文献4 046篇,其中中文文献3 334篇,英文文献712篇。白芍研究相关的年发文量整体呈上升趋势,中英文发文量最多的机构分别为北京中医药大学（76篇）和扬州大学（73篇）,发文量最多的作者分别为魏伟（24篇）、Tao Jun（66篇）。开展白芍研究的国家主要以中国为主,刊载量最多的中英文期刊分别是《中草药》和Journal of Ethnopharmacology。被引频次前10的中英文文献主要为白芍药理作用及其机制研究方向,包括抗炎、抗氧化、抗抑郁、镇痛等方面。结论 白芍研究热点集中在数据挖掘、组方规律以及白芍及其药效成分的药理作用和作用机制方面,尤其在抗氧化、抗炎、神经保护、抗抑郁、调节肠道菌群等方面的作用机制的深入研究可能是未来主要的研究趋势。     

国医大师禤国维应用酸敛法治疗小儿特应性皮炎经验

介绍禤国维教授应用酸敛法治疗小儿特应性皮炎的临床经验。认为表虚兼有表燥是本病的基本病机特点,酸敛法可调理肺气、收敛心神、收敛肝气;治疗上注重散收并用,乌梅、五味子、白芍为其最常用的酸敛药,可调理肺、心、肝三脏的功能,并通过与辛散类药物(紫苏叶、防风、蝉蜕等)的配合,达到敛阴而不留邪、祛邪而不伤正的效果。并附验案1则。     

赤芍的抑菌作用及其防治慢性牙周炎的机制研究

目的 研究赤芍提取物对牙龈卟啉单胞菌(Porphyromonas gingivalis,P.g)、具核梭杆菌(Fusobacterium nucleatum,F.n)和伴放线聚集杆菌(Actinobacillus Actinomycetes,A.a)的抑菌作用,并通过网络药理学方法分析赤芍防治慢性牙周炎(chronic...